Vertex Pharmaceuticals (VRTX) analyst forecast and price target
Analyst forecast
Consensus of 32 analyst ratings
Based on 8 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Barclays | Maintained | Overweight | $617.00 from $615.00 | Aug 5, 2026 |
| Truist Securities | Maintained | Buy | $565.00 from $560.00 | Aug 5, 2026 |
| Cantor Fitzgerald | Maintained | Overweight | $595.00 from $590.00 | Aug 4, 2026 |
| Canaccord Genuity | Maintained | Hold | $442.00 from $436.00 | Aug 4, 2026 |
| TD Cowen | Maintained | Buy | $550.00 from $525.00 | Aug 4, 2026 |
| Truist Securities | Maintained | Buy | $560.00 from $542.00 | Jul 13, 2026 |
| UBS | Maintained | Buy | $585.00 from $545.00 | Jul 13, 2026 |
| Baird | Maintained | Underperform | $350.00 from $330.00 | Jul 7, 2026 |
| RBC Capital | Maintained | Outperform | $570.00 from $543.00 | Jul 7, 2026 |
| Barclays | Maintained | Overweight | $615.00 from $607.00 | May 6, 2026 |
| RBC Capital | Maintained | Outperform | $543.00 from $541.00 | May 5, 2026 |
| Bernstein | Maintained | Outperform | $572.00 from $577.00 | May 5, 2026 |
| Morgan Stanley | Maintained | Overweight | $616.00 from $612.00 | May 5, 2026 |
| Canaccord Genuity | Maintained | Hold | $436.00 from $437.00 | May 5, 2026 |
| Canaccord Genuity | Maintained | Hold | $437.00 from $441.00 | Apr 30, 2026 |
| Morgan Stanley | Maintained | Overweight | $612.00 from $596.00 | Apr 10, 2026 |
| Maxim Group | Upgraded | Hold → Buy | $575.00 | Mar 18, 2026 |
| Truist Securities | Maintained | Buy | $525.00 from $490.00 | Mar 11, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $641.00 from $591.00 | Mar 10, 2026 |
| Oppenheimer | Maintained | Outperform | $600.00 from $540.00 | Mar 10, 2026 |
Frequently asked questions
What is the price target for VRTX stock?
The average 12-month analyst price target for Vertex Pharmaceuticals (VRTX) is $534.25, with a high estimate of $617.00 and a low of $350.00, across 8 analysts.
Is VRTX a buy, sell, or hold?
Analysts covering Vertex Pharmaceuticals currently average a Buy rating: 25 buy, 6 hold and 1 sell, from 32 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for VRTX?
The average price target of $534.25 implies 1.47% downside from the last price of $542.22.
What is the latest analyst rating on VRTX?
On Aug 5, 2026, Barclays maintained Vertex Pharmaceuticals at Overweight with a price target of $617.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.